Login to Your Account

UCB Licenses Keppra, Cimzia Rights in Japan in €113M Deal

By Staff Reports

Wednesday, June 11, 2008

No Abstract

Belgian firm UCB SA licensed Japanese co-promotion rights to two drugs, Keppra and Cimzia, to Otsuka Pharmaceuticals Co. Ltd. in a deal that could be worth as much as €113 million (US$174 million) to UCB.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription